Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Alzheimers Dement. 2023 Oct 18;19(Suppl 9):S74–S88. doi: 10.1002/alz.13466

Figure 4. The early-onset Alzheimer’s disease (EOAD) signature is a clinically valid biomarker of neurodegeneration in symptomatic patients with MCI or mild dementia due to EOAD.

Figure 4.

The magnitude of atrophy in the EOAD signature correlates with severity of cognitive impairment as measured by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (r = −0.33, P < 0.001) and Mini-Mental State Examination (MMSE) (r = −0.56, P < 0.001) within the entire sample (N = 236). More negative W-scores indicate more severe atrophy. Higher CDR-SB and lower MMSE scores indicate greater cognitive impairment. See Figure S4 for the results of this analysis in each cohort separately.